Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).

ABSTRACT:

Importance

No proven treatment is available for severely ill COVID-19. Therapeutic use of COVID-19 convalescent plasma (COPLA) is under investigation.

Objective

To compare the efficacy of COPLA with standard medical therapy (SMT) alone in severe COVID-19 patients.

Design, setting and participants

A multicentric, open-labelled, phase-III randomised controlled trial conducted at two treatment centres with COPLA collected at the third dedicated centre in North-India, the coordinating centre during trial from June 2020 to December 2020. The study population comprised 400 participants in the ratio of 1:1 in each treatment group.

Intervention

One group received COPLA with SMT (n=200), and another group received SMT only (n=200).

Main outcome measures

Primary o

SUBMITTER: Bajpai M 

PROVIDER: S-EPMC8987237 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature